Literature DB >> 10335764

Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I.

J R Crouse1, J Frohlich, L Ose, M Mercuri, J A Tobert.   

Abstract

A randomized, blinded, multicenter clinical trial was performed comparing low- and high-dose simvastatin (40 and 80 mg) with comparable doses of atorvastatin (20 and 40 mg) for effects on plasma concentrations of lipoproteins and apolipoprotein A-I over 12 weeks in 842 patients with elevated low-density lipoprotein cholesterol. The 2 agents reduced low-density lipoprotein cholesterol and triglycerides to a comparable degree, but simvastatin raised high-density lipoprotein cholesterol and apolipoprotein A-I more than atorvastatin, suggesting differences in metabolic effects of the 2 agents on plasma lipids and lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10335764     DOI: 10.1016/s0002-9149(99)00153-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

Review 1.  Lipoprotein changes with statins.

Authors:  Evan A Stein; Donald M Black
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

Review 2.  High-density lipoprotein subfractions and risk of coronary artery disease.

Authors:  John Morgan; Christina Carey; Anne Lincoff; David Capuzzi
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

3.  Twenty questions on atherosclerosis.

Authors:  W C Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-04

4.  PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.

Authors:  Frederick J Raal; Robert P Giugliano; Marc S Sabatine; Michael J Koren; Dirk Blom; Nabil G Seidah; Narimon Honarpour; Armando Lira; Allen Xue; Padmaja Chiruvolu; Simon Jackson; Mei Di; Matthew Peach; Ransi Somaratne; Scott M Wasserman; Rob Scott; Evan A Stein
Journal:  J Lipid Res       Date:  2016-04-21       Impact factor: 5.922

5.  Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia.

Authors:  Zahit Bolaman; Gurhan Kadikoylu; Nihat Ozgel; Cigdem Yenisey
Journal:  J Natl Med Assoc       Date:  2006-08       Impact factor: 1.798

6.  Activating peripheral arterial disease patients to reduce cholesterol: a randomized trial.

Authors:  Mary M McDermott; George Reed; Philip Greenland; Kathy M Mazor; Sherry Pagoto; Judith K Ockene; Rex Graff; Philip A Merriam; Kathy Leung; Larry Manheim; Melina R Kibbe; Barbara Olendzki; William H Pearce; Ira S Ockene
Journal:  Am J Med       Date:  2011-06       Impact factor: 4.965

Review 7.  Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.

Authors:  H S Malhotra; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.

Authors:  Jonathan Isaacsohn; Donald Hunninghake; Helmut Schrott; Carlos A Dujovne; Robert Knopp; Stuart R Weiss; Harold Bays; John R Crouse; Michael H Davidson; Leonard M Keilson; James McKenney; Stanley G Korenman; Adrian S Dobs; Evan Stein; Ronald M Krauss; Darbie Maccubbin; Meehyung Cho; Diane J Plotkin; Yale B Mitchel
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

Review 9.  Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome.

Authors:  Christopher M Rembold
Journal:  Curr Diab Rep       Date:  2004-10       Impact factor: 4.810

10.  Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions.

Authors:  Hetal D Shah; Keyur H Parikh; Milan C Chag; Urmil G Shah; Hemang A Baxi; Anish H Chandarana; Ajay M Naik; Joyal N Shah; Sangeeta Iyer; Kanan J Shah; Ramesh K Goyal
Journal:  Exp Clin Cardiol       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.